These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25545629)

  • 1. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
    Poewe W; Hauser RA; Lang A;
    Mov Disord; 2015 Apr; 30(4):589-92. PubMed ID: 25545629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease.
    Stocchi F;
    Eur J Neurol; 2014 Feb; 21(2):357-60. PubMed ID: 23790011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E; Stern MB
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
    Jankovic J; Berkovich E; Eyal E; Tolosa E
    Parkinsonism Relat Disord; 2014 Jun; 20(6):640-3. PubMed ID: 24637126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
    Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
    N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline improves quality of life in patients with early Parkinson's disease.
    Biglan KM; Schwid S; Eberly S; Blindauer K; Fahn S; Goren T; Kieburtz K; Oakes D; Plumb S; Siderowf A; Stern M; Shoulson I;
    Mov Disord; 2006 May; 21(5):616-23. PubMed ID: 16450340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.
    Hauser RA; Abler V; Eyal E; Eliaz RE
    Int J Neurosci; 2016 Oct; 126(10):942-6. PubMed ID: 26988747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
    Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ;
    Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
    Parkinson Study Group
    Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kitagawa T; Mochizuki H; Nagai M; Takahashi R
    Parkinsonism Relat Disord; 2019 Mar; 60():146-152. PubMed ID: 30205936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    Hoy SM; Keating GM
    Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
    Lang AE; Eberly S; Goetz CG; Stebbins G; Oakes D; Marek K; Ravina B; Tanner CM; Shoulson I;
    Mov Disord; 2013 Dec; 28(14):1980-6. PubMed ID: 24123383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
    Weintraub D; Hauser RA; Elm JJ; Pagan F; Davis MD; Choudhry A;
    Mov Disord; 2016 May; 31(5):709-14. PubMed ID: 27030249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.